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Pulmonary hypertension (PH) is a condition with high morbidity and mortality. Regardless of cause, PH has a 
negative effect on quality of life (1) and is life-shortening, 
even with modern treatment strategies. Right-sided heart 
catheterization (RHC) is the reference standard for PH, 
which is defined as a mean pulmonary arterial pressure 
(mPAP) of at least 25 mm Hg at rest (2).
RHC is an invasive test with a serious complication 
rate of 1% (3), so current guidelines recommend echo-
cardiography to classify patients suspected of having 
PH as having low, medium, or high risk of PH (2). 
Doppler echocardiographic measurement of systolic 
pulmonary arterial pressure requires an estimation of 
right atrial pressure; the current estimation from in-
ferior vena cava size does not enable an accurate pre-
diction of the true right atrial pressure at RHC (4). 
Echocardiography also requires tricuspid regurgita-
tion, which, while commonly seen in PH, is not al-
ways present, and severe tricuspid regurgitation causes 
erroneous low or high echocardiographic predictions 
of mPAP (5). As such, estimation of pulmonary ar-
terial pressures from echocardiography shows only 
moderate agreement with that measured with RHC 
(6), with 95% limits of agreement at Bland-Altman 
analysis ranging from +38.8 to 240.0 mm Hg (7). 
A large meta-analysis showed only modest diagnos-
tic accuracy of echocardiography for the presence of 
PH, with a sensitivity of 83% and a specificity of 72% 
(8). Furthermore, echocardiography is not possible in 
the context of severe lung disease owing to the loss of 
acoustic windows, and when it is measurable it is often 
erroneous (9).
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Purpose: To derive and test multiparametric cardiac MRI models for the diagnosis of pulmonary hypertension (PH).
Materials and Methods: Images and patient data from consecutive patients suspected of having PH who underwent cardiac MRI and 
right-sided heart catheterization (RHC) between 2012 and 2016 were retrospectively reviewed. Of 2437 MR images identified, 
603 fit the inclusion criteria. The mean patient age was 61 years (range, 18–88 years; mean age of women, 60 years [range, 18–84 
years]; mean age of men, 62 years [range, 22–88 years]). In the first 300 patients (derivation cohort), cardiac MRI metrics that 
showed correlation with mean pulmonary arterial pressure (mPAP) were used to create a regression algorithm. The performance of 
the model was assessed in the 303-patient validation cohort by using receiver operating characteristic (ROC) and x2 analysis.
Results: In the derivation cohort, cardiac MRI mPAP model 1 (right ventricle and black blood) was defined as follows: 2179 + 
loge interventricular septal angle 3 42.7 + log10 ventricular mass index (right ventricular mass/left ventricular mass) 3 7.57 + black 
blood slow flow score 3 3.39. In the validation cohort, cardiac MRI mPAP model 1 had strong agreement with RHC-measured 
mPAP, an intraclass coefficient of 0.78, and high diagnostic accuracy (area under the ROC curve = 0.95; 95% confidence interval 
[CI]: 0.93, 0.98). The threshold of at least 25 mm Hg had a sensitivity of 93% (95% CI: 89%, 96%), specificity of 79% (95% CI: 
65%, 89%), positive predictive value of 96% (95% CI: 93%, 98%), and negative predictive value of 67% (95% CI: 53%, 78%) in 
the validation cohort. A second model, cardiac MRI mPAP model 2 (right ventricle pulmonary artery), which excludes the black 
blood flow score, had equivalent diagnostic accuracy (ROC difference: P = .24).
Conclusion: Multiparametric cardiac MRI models have high diagnostic accuracy in patients suspected of having pulmonary 
hypertension.
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Image Acquisition
Cardiac MRI was performed with a 1.5-T whole-body imager 
(HDx; GE Healthcare, Milwaukee, Wis), with the patient su-
pine, by using an eight-channel cardiac coil. Standard four-
chamber and short-axis balanced steady-state free precession 
cine stack images were acquired from base to apex. Phase con-
trast imaging was performed orthogonal to the main pulmo-
nary artery. Black blood imaging of the pulmonary arteries 
was performed by using a double inversion recovery fast spin-
echo sequence, acquiring images with 8-mm-thick sections 
through the main and branch pulmonary arteries (12). The 
sequence parameters are provided in Appendix E1 (online).
Image Analysis
MR images were manually analyzed by D.A.C. (an MRI ra-
diographer with 9 years of cardiac experience) with use of 
an Advantage workstation (version 4.4, GE Healthcare) with 
ReportCard software (GE Healthcare). Analysis was per-
formed prospectively and sequentially at the time of imag-
ing, with remote supervision by A.J.S. (a consultant cardiac 
radiologist with 12 years of experience) when required. Im-
age analysis was performed before RHC and while blinded to 
all other clinical details. The results of the analysis and, fre-
quently, the contours were reviewed at the weekly multidisci-
plinary meeting, and any studies that were not of diagnostic 
quality were excluded. All cardiac MRI metrics outlined be-
low were remeasured in 15 randomly selected studies from 
the validation cohort by a second reviewer (C.S.J., a general 
radiologist with 6 years of experience) who was blinded to the 
findings of the previous analysis and to all clinical data.
Left and right ventricular end-diastolic volume, end-sys-
tolic volumes, and right and left ventricular stroke volume 
and mass were calculated (indexed to body surface area) and 
right and left ventricular ejection fraction, ventricular mass 
index (right ventricular mass divided by left ventricular mass) 
(13,14), and interventricular septal angle were measured as 
previously described (15–17). Maximal and minimal pul-
monary artery areas were manually traced, and relative area 
change was defined as follows: pulmonary artery relative area 
change = (maximum area 2 minimum area)/minimum area 
(18,19). Pulmonary artery average velocity was calculated by 
using the phase contrast flow as forward pulmonary artery 
velocity/diastolic pulmonary artery size (Fig 2). The repro-
ducibility of these cardiac MRI metrics between the reviewer 
D.A.C. (MR radiographer) and A.J.S. (consultant cardiac 
radiologist) has been previously published in a cohort of pa-
tients with pulmonary arterial hypertension (group 1) (20).
Black blood slow flow was visually scored by A.J.S. by using a 
semiquantitative scale from 0 to 5 depending on how proximal 
the flow feature is seen in the pulmonary arterial tree (Fig 3), 
as follows: 0 = absent, 1 = segmental, 2 = lobar, 3 = distal main, 
4 = proximal main, and 5 = trunk. This scale has been shown 
to have good interobserver reproducibility (21).
Right-sided Heart Catheterization
RHC was performed as part of the routine clinical pathway 
by the PH clinicians (D.G.K., C.E., and R.C.), all with more 
Abbreviations
CI = confidence interval, mPAP = mean pulmonary arterial pressure, 
PH = pulmonary hypertension, RHC = right-sided heart catheteriza-
tion, ROC = receiver operating characteristic
Summary
A cardiac MRI diagnostic model for the identification of pulmonary 
hypertension, incorporating measurements from the right ventricle 
and pulmonary artery, accurately correlates with right-sided heart 
catheterization–measured mean pulmonary arterial pressure and 
represents a noninvasive method to assess the diagnosis of pulmonary 
hypertension.
Implications for Patient Care
 n The mean pulmonary arterial pressure determined with a cardiac 
MRI model that includes the angle of the interventricular septum, 
ventricular mass index, and the extent of black blood slow flow 
correlated with that measured with right-sided heart catheteriza-
tion.
 n Cardiac MRI parameters can help identify patients with high sen-
sitivity (93%) and moderate specificity (79%).
A number of cardiac MRI metrics have been proposed as pre-
dictors of increased pulmonary arterial pressure, and a number 
of image-based models (physiologic, empirical, and computa-
tional) have been proposed. Black blood scoring has been shown 
to be a useful diagnostic marker in PH; however, it is not widely 
adopted in MRI protocols. Thus, developing models with and 
without this parameter would be advantageous. Previously iden-
tified cardiac MRI metrics and markers have been tested in rela-
tively small numbers and often have modest diagnostic accuracy.
We hypothesized that (a) cardiac MRI parameters from 
both the heart and pulmonary arteries have additive diagnos-
tic value in patients suspected of having PH and (b) a cardiac 
MRI multiparametric model could help diagnose PH with 
high accuracy.
The aim of this study was to derive two regression models, 
one with and one without black blood scoring, to diagnose PH 
with use of cardiac and pulmonary vascular cardiac MRI.
Materials and Methods
Patients
Consecutive incident patients suspected of having PH who 
were referred to a tertiary PH center from April 2012 to 
October 2016 were identified from the ASPIRE database 
(Assessing the Spectrum of Pulmonary Hypertension Identi-
fied at a Referral Center) (10). Patients were separated by date 
of imaging into a derivation (n = 300) and a validation (n = 
303) cohort. Only incident patients who underwent cardiac 
MRI and RHC within 14 days were included. Any patient 
with a left atrial volume index of 41 mL or higher at cardiac 
MRI was excluded as this is a potential marker of PH due to 
left-sided heart disease (11). Figure 1 shows the process of 
patient selection. Treatment was always initiated after RHC 
and cardiac MRI had been performed. Ethical approval was 
granted from a local ethics committee for this retrospective 
study, and the requirement to obtain informed written con-
sent was waived (ref c06/Q2308/8).
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black blood slow flow, and diagnostic accuracy 
was calculated with the same method.
Validation cohort.—The second half of the patients 
(n = 303) was used for validation. The correlation 
of the derived regression equations for PH diagno-
sis against RHC-measured mPAP was calculated. 
The accuracy of these models was assessed with 
Bland-Altman analysis, and the intraclass correla-
tion coefficient was calculated between the model- 
and RHC-measured mPAP (two-way mixed effects 
model, absolute agreement definition, and single 
measures). Their diagnostic performance was as-
sessed by using ROC curve analysis, sensitivity, 
specificity, negative and positive predictive values, 
and negative and positive likelihood ratios. For 
comparison of ROC curves, we used a nonpara-
metric method that is analogous to the Wilcoxon–
Mann-Whitney test. Reproducibility between 
D.A.C. and C.S.J. was analyzed with the intraclass 
correlation coefficient by using a two-way mixed ef-
fects model and average measures.
Results
Patients
The ASPIRE MRI subregistry contains 2437 car-
diac MR images, and within this there are 1272 
incident images with suspected PH. Of the patients with in-
cident images, 957 underwent RHC and cardiac MRI within 
14 days. Of those 957 patients, 603 had a left atrial volume 
index of less than 41 mL. The first 300 patients were used as 
the derivation cohort and the second 303 as the validation 
cohort (Figure 1). Baseline characteristics of the patients are 
provided in Table 1. Apart from cardiac index, there were no 
significant differences in the clinical demographics of patients 
between derivation and validation cohorts (Table 2). The dif-
ference in cardiac index between the two groups was very 
small and unlikely to be of clinical significance, as outlined 
in Table 1. Fifty-two patients in the derivation cohort and 45 
in the validation cohort did not have PH. In total, there were 
97 patients who did not have PH, 264 patients with pulmo-
nary arterial hypertension, 11 with PH due to left-sided heart 
disease (even after exclusion of dilated left atria), 60 with PH 
due to respiratory disease, 157 with chronic thromboembolic 
disease, and 18 with PH due to unclear or multifactorial 
mechanisms. Three hundred fifteen patients were excluded 
because MRI was performed more than 14 days from RHC. 
This excluded group consisted of 37 patients without PH, 
154 patients with group 1 pulmonary arterial hypertension, 
19 with PH due to left-sided heart disease, 16 with PH due to 
lung disease, 81 with chronic thromboembolic PH, and eight 
with unclear causes.
Derivation Cohort
The strongest correlations with mPAP were for systolic inter-
ventricular septal angle, black blood score, right ventricular 
than 10 years of experience, by using a balloon-tip 7.5-F ther-
modilution catheter (Becton-Dickinson, Franklin Lakes, NJ). 
PH was defined as a resting mPAP of 25 mm Hg or higher (2).
Statistical Analysis
Statistical analysis was performed with software (SPSS 22; IBM, 
Chicago, Ill), and graphs were produced by using GraphPad 
Prism (GraphPad Software, La Jolla, Calif ). Unless otherwise 
stated, P , .05 was considered indicative of a statistically sig-
nificant difference. Comparison of continuous variables between 
groups was made by using the Student t test and the x2 test for 
discrete variables.
Derivation cohort.—The first 300 patients were used as a 
derivation cohort to derive diagnostic PH models. The Pear-
son correlation coefficients between quantifiable cardiac MRI 
characteristics and mPAP were calculated. As multiple cor-
relations were assessed, the risk of type 1 error was reduced 
by using Bonferroni correction, so P , .002 was considered 
indicative of a statistically significant difference (30 different 
correlations). Scatterplots were constructed to ensure linear-
ity between cardiac MRI metrics and mPAP. Any significant 
correlations were used to calculate a linear regression equa-
tion for estimation of mPAP. A receiver operating characteris-
tic (ROC) curve was constructed to assess suitable diagnostic 
thresholds, one that was highly specific and one that had a 
balance of specificity and sensitivity (the Youden index). A 
second regression equation was calculated without the use of 
Figure 1: Patient flowchart.
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ventricular mass index and loge of septal angle were used in 
further calculations.
Regression analysis, performed in a forward direction for any 
metric that showed a correlation with mPAP (P , .2), produced 
the following equation: cardiac MRI mPAP model 1 (right ven-
tricle and black blood) = 2179 + loge interventricular septal angle 
3 42.7 + log10 ventricular mass index (right ventricular mass/left 
ventricular mass) 3 7.57 + black blood slow flow score 3 3.39.
A threshold of at least 25 mm Hg was identified as having an 
optimal diagnostic threshold (Youden index), with a sensitivity 
of 96% and a specificity of 73%.
After exclusion of black blood slow flow, the following re-
gression equation was derived: cardiac MRI mPAP model 2 
ejection fraction, right ventricular end-systolic volume index, 
and ventricular mass index (R = 0.74, 95% confidence in-
terval [CI]: 0.69, 0.79; R = 0.69, 95% CI: 0.63, 0.75; R = 
20.60, 95% CI: 20.53, 0.67; R = 0.59, 95% CI: 0.51, 0.65; 
and R = 0.53, 95% CI: 0.44, 0.61, respectively). Higher right 
ventricular volumes (end-diastolic and end-systolic volumes), 
lower left atrial volume index and left ventricular end dia-
stolic volume, larger pulmonary artery size, and lower pul-
monary arterial relative area change and velocity all showed 
statistically significant correlation with higher mPAP (see 
Table E1 [online] for the data). Visual inspection of the scat-
terplots of interventricular septal angle and ventricular mass 
index revealed an exponential relationship, so the log10 of the 
Figure 3: Semiquantitative scoring of black blood slow flow score. The score is based on how proximal signal can be seen in pulmonary arter-
ies, where 0 = no slow flow, 1 = signal within segmental pulmonary arteries, 2 = signal within lobar branches, 3 = signal within distal main pul-
monary artery, 4 = signal within proximal main pulmonary artery, and 5 = signal within proximal main pulmonary artery. Diagram demonstrates 
different parts of pulmonary artery and naming convention. Example images of each score are provided with their mean pulmonary artery pres-
sure (mPAP) as a reference.
Figure 2: Representative steady-state free precession short-axis cine images of pulmonary artery demonstrate calculation of the quantitative 
metrics pulmonary arterial relative area (left), with systolic pulmonary artery size shown as solid line and diastolic pulmonary artery size shown as 
dotted line, ventricular mass index (middle), with right ventricular mass shown as dotted area and left ventricular mass shown as solid lined area, 
and interventricular septal angle (right), shown by solid line. LV = left ventricle, RV = right ventricle.
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identified as having an optimal di-
agnostic threshold.
Validation Cohort
Agreement.—Cardiac MRI 
mPAP model 1 correlated strongly 
with RHC-measured mPAP (R = 
0.80; 95% CI: 0.75, 0.84). Bland-
Altman analysis showed a small 
bias (3.9%), with reasonable 95% 
agreement (242% to 50%) and an 
excellent intraclass correlation coef-
ficient for the estimation of mPAP 
of 0.78 (95% CI 0.73, 0.83). The 
cardiac MRI mPAP model 2 also 
strongly correlated with mPAP (R 
= 0.80; 95%: CI: 0.76, 0.85), with a small bias (0.9%) and again 
reasonable 95% agreement (243% to 46%), with an intraclass 
correlation coefficient of 0.79 (95% CI: 0.73, 0.83). Figure 4 
shows the scatterplots and Bland-Altman plots for cardiac MRI 
mPAP models 1 and 2.
(right ventricle pulmonary artery) = 2231.423 + loge inter-
ventricular septal angle 3 53.8 + log10 ventricular mass in-
dex (right ventricular mass/left ventricular mass) 3 8.708 + 
diastolic pulmonary artery area 3 0.009. For cardiac MRI 
mPAP model 2, the threshold of at least 25 mm Hg was again 
Table 1: Baseline Demographics for All Patients according to PH Status and Derivation or Validation Cohort
Parameter No PH (n = 97) PH (n = 506) P Value
Derivation Cohort  
(n = 300)*
Validation Cohort  
(n = 303)† P Value
Age (y) 56 6 16 52 6 13 ,.001 60 6 14 61 6 14 .28
Sex‡ .10 .24
 F 66 299 189 176
 M 31 207 111 127
WHO functional class‡ ,.001 .08
 I 0 1 0 1
 II 35 29 34 30
 III 50 409 223 236
 IV 3 60 33 30
ISWT (m) 308 6 223 211 6 182 ,.001 228 6 184 223 6 198 .78
mPAP (mm Hg) 19 6 3 47 6 13 ,.001 42 6 16 42 6 15 .94
mRAP (mm Hg) 5.7 6 2.9 11 6 6 ,.001 10 6 6 10 6 6 .32
PAWP (mm Hg) 10 6 4 11 6 4 .01 11 6 4 11 6 4 .22
Cardiac index (L/min/m2) 3.1 6 0.76 2.5 6 0.76 ,.001 2.8 6 0.8 2.5 6 0.8 ,.001
PVRI (dyne · sec · m2/cm5) 74 6 41 390 6 253 ,.001 326 6 241 345 6 277 .38
SvO2 (%) 71 6 7 63 6 9 ,.001 64 6 9 64 6 9 .93
FEV1 (% predicted) 74 6 11 68 6 13 ,.001 78 6 24 78 6 25 .89
FVC (% predicted) 84 6 19 80 6 25 .25 82 6 23 80 6 24 .86
FEV1/FVC 74 6 12 68 6 13 ,.001 68 6 13 70 6 12 .24
TLCO (% predicted) 62 6 18 43 6 22 ,.001 46 6 23 46 6 21 .98
Time between RHC and MRI (d) 1 6 2 1 6 2 .65 1 6 2 1 6 2 .59
Note.—Except where indicated, data are means 6 standard deviations. P values were calculated by using the Student t test for continuous 
variables and the x2 test for discrete variables. FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, ISWT = incre-
mental shuttle walk test, mPAP = right-sided heart catheterization–measured mean pulmonary arterial pressure, mRAP = mean right atrial 
pressure, PAWP = pulmonary artery wedge pressure, PH = pulmonary hypertension, PVRI = pulmonary vascular resistance index, RHC = 
right-sided heart catheterization, SvO2 = mixed venous oxygen saturation, TLCO = transfer factor for carbon monoxide, WHO = World 
Health Organization.
* There were 52 patients without PH and 218 with PH.
† There were 45 patients without PH and 258 with PH.
‡ Data are numbers of patients.
Table 2: Diagnostic Performance of Models 1 and 2
Parameter Model 1 Model 2
Correlation with RHC-measured mPAP 0.80 (0.75, 0.84) 0.80 (0.76, 0.85)
ICC with mPAP 0.78 (0.73, 0.83) 0.79 (0.73, 0.83)
Sensitivity (%) 93 (89, 96) 92 (88, 95)
Specificity (%) 79 (65, 89) 59 (43, 74)
Positive predictive value (%) 96 (93, 98) 94 (90, 96)
Negative predictive value (%) 67 (53, 78) 51 (37, 65)
Positive likelihood ratio 4.4 2.2
Negative likelihood ratio 0.09 0.14
AUC 0.95 (0.93, 0.98) 0.93 (0.90, 0.96)
Interobserver reproducibility 0.94 (0.81, 0.98) 0.88 (0.64, 0.96)
Note.—Numbers in parentheses are 95% confidence intervals. AUC = area under the receiver 
operating characteristic curve, ICC = intraclass correlation coefficient, mPAP = mean pulmonary 
arterial pressure, RHC = right-sided heart catheterization.
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Interobserver reproducibility analysis showed an intraclass 
correlation coefficient of 0.94 (95% CI: 0.81, 0.98) for car-
diac MRI mPAP model 1 and 0.88 (95% CI: 0.64, 0.96) for 
cardiac MRI mPAP model 2.
Discussion
Interventricular septal angle, ventricular mass index, and black 
blood slow flow score were independent cardiac MRI predic-
tors of mean pulmonary arterial pressure (mPAP), with addi-
tive value for the diagnosis of pulmonary hypertension (PH). 
We have derived a linear regression model, a composite of these 
three measurements (in 300 patients), and have shown high 
diagnostic accuracy in a large validation cohort (a further 303 
patients), identifying a threshold of at least 25 mm Hg as the 
optimal threshold, equivalent to that with RHC.
Our proposed cardiac MRI mPAP 1 (right venticle and 
black blood) model comprises measurement of displacement 
of the interventricular septum (a marker of the pressure and 
volume differential between the left and right ventricle), re-
modeling of the right ventricle (ventricular mass index), and 
slow or turbulent flow in the pulmonary artery at black blood 
imaging. These measurements are easily acquired from stan-
dard cardiac MRI sequences, require little postprocessing time, 
and are reproducible (20). Black blood pulmonary arterial flow 
score is a reproducible marker of outcome in pulmonary arte-
rial hypertension (21). In healthy individuals, the protons in 
the pulmonary artery that are excited are replaced by nonex-
cited protons from outside the field of view. In patients with 
PH, the excited protons within the pulmonary artery remain, 
Diagnostic accuracy.—Cardiac MRI mPAP model 1 
showed high diagnostic accuracy (area under the ROC curve 
= 0.95; 95% CI: 0.93, 0.98). The threshold of at least 25 mm 
Hg had a sensitivity of 93% (95% CI: 89%, 96%), specificity 
of 79% (95% CI: 65%, 89%), positive predictive value of 
96% (95% CI: 93%, 98%), negative predictive value of 67% 
(95% CI: 53%, 78%), positive likelihood ratio of 4.4, and 
negative likelihood ratio of 0.09.
Cardiac MRI mPAP model 2 (25 mm Hg) had a sensitiv-
ity of 92% (95% CI: 88%, 95%), specificity of 59% (95% CI: 
43%, 74%), positive predictive value of 94% (95% CI: 90%, 
96%), negative predictive value of 51% (95% CI: 37%, 65%), 
positive likelihood ratio of 2.2, and negative likelihood ratio 
of 0.14. ROC curve analysis of cardiac MRI mPAP model 2 
showed an area under the ROC curve of 0.93 (95% CI: 0.90, 
0.96). There was no significant difference in the area under the 
ROC curve between these models (P = .24). Figure 5 shows the 
ROC curves for both models, and Table 2 provides a summary 
of the diagnostic performance of both models.
After exclusion of all patients with PH due to left-sided heart 
disease, in addition to exclusion of patients with a left atrial vol-
ume index of less than 41 mL, cardiac MRI mPAP model 1 had 
a sensitivity of 94% (95% CI: 91%, 97%), specificity of 79% 
(95% CI: 65%, 89%), positive predictive value of 96% (95% 
CI: 93%, 98%), and negative predictive value of 72% (95% CI: 
58%, 83%). Cardiac MRI mPAP model 2 had a sensitivity of 
94% (95% CI: 91%, 97%), specificity of 51% (95% CI: 37%, 
65%), positive predictive value of 92% (95% CI: 88%, 94%), 
and negative predictive value 61% (95% CI: 45%, 75%).
Figure 4: A, B, Scatterplots show correlation of, A, cardiac MRI (CMR) mean pulmonary arterial pressure (mPAP) model 1 
(the model based on metrics from right ventricle and slow flow at black blood imaging) and, B, cardiac MRI mPAP model 2 
(the model based on metrics of the pulmonary artery and right ventricle) with right-sided heart catheterization–measured mPAP 
in validation cohort. C, D, Corresponding Bland-Altman plots. Dotted line shows bias and dashed lines show 95% levels of 
agreement.
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Our study has some limitations, including its single-center, 
retrospective design. To further assess the validity of our models, 
analysis of a further cohort of patients suspected of having PH is 
required at a different center. In addition, it is necessary to validate 
the models in a cohort with a relatively lower proportion of pa-
tients with PH. The tertiary referral center population potentially 
limits its applicability in the wider clinical setting. Black blood 
imaging may not be available in some centers, or sequence param-
eters may differ between centers. In these instances, cardiac MRI 
mPAP model 2 (right ventricle pulmonary artery) may be used 
based on the interventricular septal angle, ventricular mass index, 
diastolic pulmonary arterial size, and pulmonary arterial relative 
area change. The limits of agreement of cardiac MRI models are 
insufficient for accurate estimation of an individual mPAP value. 
However, diagnostic accuracy is high as a diagnostic test at the 
threshold of 25 mm Hg.
In conclusion, cardiac MRI has high diagnostic accuracy 
in a cohort of incident patients referred to a tertiary referral 
center with suspected pulmonary hypertension (PH). A re-
producible model comprising simple and easy-to-obtain met-
rics (interventricular septal angle, ventricular mass index, and 
black blood score) can enable the identification of patients 
with PH with high accuracy. This model may improve the de-
tection rates of PH and enhance the noninvasive assessment 
of patients with this severe disease.
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returning signal. This is likely to be a composite of slow flow 
and vortical or turbulent flow within the pulmonary artery. 
The increasing use of four-dimensional phase-contrast flow im-
aging will likely allow this metric within the model to be im-
proved upon (22–24). The parameters of black blood imaging 
that are susceptible to flow artifacts (section thickness, inver-
sion time, echo time, echo train length, and cardiac triggering 
point) were kept the same between patients and could be easily 
adopted for standardized use in different centers.
Previous studies have shown that the measurement of septal 
deviation has diagnostic value in suspected PH (25); in addi-
tion, it has been shown previously that the addition of ventricu-
lar mass index to a measure of septal angle increased diagnostic 
accuracy (15). The current larger study further validates these 
observations and identifies that the addition of a measurement 
from the pulmonary vasculature increases diagnostic accuracy 
(ie, black blood slow flow score or pulmonary artery size in di-
astole). Computational models of pulmonary arterial flow have 
also been assessed for the diagnosis of PH (26). Further work to 
integrate such physiologic models would be of value.
In patients with PH due to left-sided heart disease, treatment 
is aimed at the underlying cause (often left ventricular diastolic 
dysfunction) and not at the pulmonary vasculature. As such, 
current guidelines recommend that patients suspected of having 
PH but who have left-sided heart disease and no features of se-
vere PH should not be referred to specialist centers (2). We have 
considered this recommendation in our patient selection, using 
cardiac MRI–derived left atrial volume index (27) (41 mL/
m2) as a cardiac MRI marker for the presence of left-sided heart 
disease (11). Further work is required to improve the identifica-
tion of patients with PH due to left-sided heart disease by using 
cardiac MRI metrics such as transmitral flow and left atrial and 
ventricular filling.
Figure 5: Receiver operating characteristics (ROC) curve for 
cardiac MRI mean pulmonary arterial pressure (mPAP) models 
1 and 2. There is no significant difference between the two 
curves (P = .24). AUC = area under the ROC curve.
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